Three-arm trial (n = 300)
| two-arm trial (n = 200)
| Enrollment
|
• 36 weeks SMT + SRE (n = 88)
| • 36 weeks SMT + SRE (n = 100)
| Funding
|
• 12 weeks SMT + SRE (n = 124)
| • 12 weeks SMT + SRE (n = 100)
|
|
• 36 weeks SRE alone (n = 88)
|
|
|
n = 300
| n = 200 (for primary and secondary aims 1–4)
| Enrollment
|
n = 18 (for additional secondary aims A-C)
| Funding
|
Randomization ratio 1:1.4:1
| Final randomization ratio 1:1
| Enrollment
|
Funding
|
Pertinent inclusion/exclusion criteria:
| Pertinent inclusion/exclusion criteria:
| Enrollment
|
• NDI and ODI ≥ 15% each at both baseline evaluations
| • NDI and ODI ≥ 10% each AND combined score of ≥ 25% at first baseline evaluation only
|
Functional outcomes:
| Functional outcomes:
| Funding |
• short physical performance battery
|
• hand grip strength
|
• accelerometry
| • short physical performance battery
|
• postural sway
| • hand grip strength
|
• range of motion
| • accelerometry |
• static endurance |